However, studies on the recent vaccine for COVID-19 treatment demonstrated that the increase of anti-PEG IgM was recorded only after the first dose and no severe adverse reactions were observed in subjects that presented high levels of anti-PEG IgM even before the first dose administration [76]. Here, CD40LG is linked to COVID-19.